CSL Of Australia Could Face Roadblock To U.S. Approval Of Talecris Buy
This article was originally published in PharmAsia News
Executive SummaryAustralia's CSL may have trouble getting the approval of U.S. authorities for its acquisition of Talecris Biotherapeutics. The $3.1 billion deal for the blood products company was announced last August, but at least one analyst noted U.S. administrations have changed since then to give greater attention to regulation. The fear is the Federal Trade Commission will block the merger because it would give CSL too much of the blood products market. (Click here for more
You may also be interested in...
Phase Ib data at ASH look competitive with new pivotal trial results for Bristol/bluebird’s leading BCMA CAR-T bb2121. The Phase II portion of the CARTITUDE-1 study for JNJ-4528 is fully enrolled.
Farah Ahmed, president and CEO of the Fragrance Creators Association, discusses the trade group’s expansion in recent years beyond immediate regulatory and legislative concerns to a platform for robust member collaboration in the name of positively impacting the world.